

1 **Impact of State Telehealth Parity Laws for Private Payers on Hypertension Management**
2 **before and during the COVID-19 Pandemic**
3

4 Donglan Zhang, PhD^{1,2*}; Jun Soo Lee, PhD^{3*}; Adebola Popoola, JD, MPH, MBS³; Sarah Lee,
5 BS¹; Sandra L. Jackson, PhD, MPH³; Lisa M. Pollack, PhD, MPH, MPT³; Xiaobei Dong, PhD⁴;
6 Nicole L. Therrien, PharmD, MPH³; and Feijun Luo, PhD³
7

8 * Donglan Zhang and Jun Soo Lee are joint 1st authors with equal contributions.
9

10 **Author Affiliations:**

11 ¹ Center for Population Health and Health Services Research, Department of Foundations of
12 Medicine, New York University Grossman Long Island School of Medicine, Mineola, NY

13 ² Department of Population Health, New York University Grossman School of Medicine, New
14 York, NY

15 ³ Division for Health Disease and Stroke Prevention, Centers for Disease Control and
16 Prevention, Atlanta, GA

17 ⁴ Joseph J. Zilber School of Public Health, University of Wisconsin-Milwaukee, Milwaukee, WI
18
19

20 **Correspondence to:**

21 Feijun Luo, PhD

22 Economist

23 Division for Health Disease and Stroke Prevention

24 Centers for Disease Control and Prevention

25 Phone: 770-488-3896

26 Email: htol1@cdc.gov
27

28 **Word count:** abstract: 351; main text: 3,726
29

30 **Conflict of Interest Disclosures:** None
31

32 **Funding:** None
33

34 **Disclaimer:** The findings and conclusions in this report are those of the authors and do not
35 necessarily represent the official position of the Centers for Disease Control and Prevention. Use
36 of trade names and commercial sources is for identification only and does not imply endorsement
37 by the U.S. Department of Health and Human Services.
38

39 **Acknowledgments:** The authors are genuinely grateful to Michael Schooley (Centers for Disease
40 Control and Prevention) for his guidance, suggestions, and article review. The authors also thank
41 researchers at NORC at the University of Chicago who assisted with collection and coding of
42 state telehealth laws.
43

44 **Abstract**

45 **BACKGROUND:** Telehealth has emerged as an effective tool for managing common chronic
46 conditions such as hypertension, especially during the COVID-19 pandemic. However, the
47 impact of state telehealth payment and coverage parity laws on hypertension management
48 remains uncertain.

49
50 **METHODS:** Data from the Merative™ MarketScan® Commercial Claims and Encounters
51 Database from January 1, 2016 to December 31, 2021 were used to construct the study cohort.
52 The sample included non-pregnant individuals aged 25–64 years with hypertension. We
53 reviewed and coded telehealth parity laws related to hypertension management in all 50 states
54 and the District of Columbia, distinguishing between payment parity laws and coverage parity
55 laws. The primary outcomes were antihypertension medication use, measured by the average
56 medication possession ratio (MPR), medication adherence (MPR \geq 80%), and average number of
57 days of drug supply. We used a generalized difference-in-difference (DID) design to examine the
58 impact of these laws. Results were presented as marginal effects and 95% confidence intervals
59 (CI).

60
61 **RESULTS:** Among 353,220 individuals, states with payment parity laws were significantly
62 linked to increased average MPR by 0.43 percentage point (95% CI: 0.07 - 0.79), and an increase
63 of 0.46 percentage point (95% CI: 0.06 - 0.92) in the probability of medication adherence.
64 Payment parity laws also led to an average increase of 2.14 days (95% CI: 0.11 - 4.17) in
65 antihypertensive drug supply, after controlling for state-fixed effects, year-fixed effects,
66 individual sociodemographic characteristics and state time-varying covariates including
67 unemployment rates, GDP per capita, and poverty rates. In contrast, coverage parity laws were
68 associated with a 2.13-day increase (95% CI: 0.19 - 4.07) in days of drug supply, but did not
69 significantly increase the average MPR or probability of medication adherence. In addition,
70 telehealth payment or coverage parity laws were positively associated with the number of
71 hypertension-related telehealth visits, but this effect did not reach statistical significance. These
72 findings were consistent in sensitivity analyses.

73
74 **CONCLUSIONS:** State telehealth payment parity laws were significantly associated with
75 greater medication adherence, whereas coverage parity laws were not. With the increasing
76 adoption of telehealth parity laws across states, these findings may support policymakers in
77 understanding potential implications on management of hypertension.

78 **Clinical Perspective**

79 **What Is New?**

80

81 Telehealth is an effective tool to manage hypertension and state-level telehealth parity laws can
82 influence its application. Prior studies have not clearly differentiated between the impacts of
83 payment parity and coverage parity. Using a quasi-experimental generalized difference-in-
84 differences design, we assessed the effects of telehealth payment parity and coverage parity laws
85 on hypertension management.

86

87 Our study found that state telehealth payment parity laws were significantly associated with
88 increased hypertension medication adherence, while coverage parity laws were not.

89

90 **What Are the Clinical Implications?**

91

92 The widespread adoption of telehealth payment parity laws may significantly impact
93 hypertension management, during emergencies like the COVID-19 pandemic and beyond.

94

95 Considering that hypertension impacts approximately half of the adult population, our study
96 provides valuable insights into the potential benefits of telehealth parity laws for private payers
97 in enhancing the management of hypertension.

98

99 With the increasing adoption of telehealth parity laws across states, integrating telehealth into
100 hypertension management holds significant implications for the evolving U.S. healthcare system
101 in the digital age.

102 INTRODUCTION

103 The COVID-19 pandemic brought about unprecedented changes in healthcare, leading to
104 a rapid expansion of telehealth services to compensate for deferred medical care. Telehealth
105 emerged as a critical and robust tool in managing prevalent chronic conditions like
106 hypertension.^{1,2} Telemedicine for hypertension is especially well-received, with one report
107 claiming an average adherence to telemedicine-based hypertension management programs as
108 high as 77%.² However, telehealth adoption has been largely influenced by state policies,
109 particularly those governing private payers' (otherwise known as private insurance, primarily
110 funded through benefits plans provided by employers) reimbursement. In contrast to public
111 payers like Medicare and Medicaid, private payers covered over half of insured individuals.³
112 Despite the growing importance of telehealth, little is known about the impact of different state
113 telehealth policies for private payers on hypertension management.

114 Telehealth parity requirements typically fall into two distinct types. The first type is
115 "payment parity," which requires that payments for telehealth services match those for in-person
116 care. Payers must reimburse telehealth services at the same rate or amount as they would for in-
117 person visits.^{4,5} The second type is "coverage parity," which mandates that services covered in-
118 person must also be covered via telehealth, though not necessarily at an equal amount as in in-
119 person care.^{4,5} This means the same services are eligible for coverage, but reimbursement rates
120 may vary between telehealth and in-person visits. Previous research has explored the association
121 of telehealth parity laws with various outcomes. For example, two studies found that utilization
122 of telehealth services significantly increased in parity versus non-parity states.^{6,7} In addition,
123 studies have shown similar or better clinical outcomes for patients receiving telehealth care
124 compared with in-person care in various clinical settings.^{8,9} However, these studies often

125 overlooked the differentiation between “payment parity” and “coverage parity” when
126 investigating the effects of parity. Some states have coverage laws in place, indicating that
127 telehealth services are eligible for coverage, but they might not mandate payment parity, and vice
128 versa.¹⁰ The distinction between these types of parity is crucial, as it can significantly impact
129 access to telehealth services and reimbursement rates for healthcare providers. Moreover, prior
130 research on telehealth has been limited to other settings or services, such as mental health care
131 and psychotherapy,^{11, 12} and has not specifically assessed hypertension treatment, particularly for
132 private payers.

133 This study aims to fill a gap in the literature by separately investigating the impact of
134 state telehealth payment parity laws and coverage parity laws on hypertension management
135 before and during the COVID-19 pandemic. As outlined in Anderson's behavioral model,¹³
136 insurance policy serves as a vital enabling factor for physicians to provide essential care to
137 patients with chronic conditions and encourage patients to seek healthcare services. In the
138 context of hypertension management, consistent follow-up for medication prescriptions,
139 conducted via telehealth or in-person consultations, and adhering to antihypertensive medication
140 regimens are key strategies to improve hypertension control.^{14,15} Thus, we hypothesize by
141 providing insurance coverage for telehealth services, telehealth parity laws can enhance
142 hypertension management by improving care and medication adherence. Our findings have
143 important implications for policymakers, clinicians, and patients seeking to enhance the use of
144 telehealth for hypertension management.

145 **METHODS**

146 **Data Source**

147 We used data from the Merative™ MarketScan® Commercial Claims and Encounters
148 (CCAIE) Database from January 1, 2016 to December 31, 2021.¹⁶ The MarketScan® CCAIE
149 Database comprises patient-level administrative medical and outpatient drug claims, covering
150 millions of U.S. individuals. The CCAIE Database consists of more than 120 large employers and
151 more than 30 health plans, with 27.5+ and 17.2+ million enrollees in 2016 and 2021,
152 respectively. The CCAIE Database includes claims data for individuals from all 50 U.S. states
153 and the District of Columbia (DC), although the distribution is uneven across the regions. The
154 inclusion of unique identifiers in the database allowed for continuous tracking of the same
155 individuals over time. This study employed secondary data analysis, using de-identified
156 information; thus, no review by the Institutional Review Board at New York University
157 Grossman School of Medicine or the Centers for Disease Control and Prevention was deemed
158 necessary. The authors cannot share the MarketScan® commercial claims database publicly due
159 to the data user agreement, but the program codes will be available upon request to the
160 corresponding author.

161

162 **Study Sample**

163 The study sample included individuals aged 25–64 years as of December 31, 2021. To be
164 included, individuals were required to have had a hypertension diagnosis (International
165 Classification of Diseases, 10th Revision, Clinical Modification [ICD-10-CM] of I10-I15) during
166 the years 2016–2017, identified as ≥ 1 inpatient or ≥ 2 outpatient visits at least 30 days apart
167 (Appendix Table 1). Furthermore, individuals were required to have had ≥ 1 drug claim for an

168 antihypertensive medication. We identified seven antihypertensive therapeutic classes, including
169 ACE inhibitors, angiotensin receptor blockers, beta-blockers, calcium channel blockers,
170 diuretics, renin-angiotensin system antagonists, and other antihypertensives, along with the
171 corresponding generic drug names (Appendix Table 2).

172 To ensure data quality and consistency, we excluded individuals who were not
173 continuously enrolled in a health plan, had a pregnancy-associated diagnosis (Appendix Table
174 1),^{17, 18} or were covered by capitated health insurance (as healthcare utilization and costs are not
175 fully captured among those with capitated health insurance) during our study period (2016 to
176 2021). Participants were also excluded if any state identifiers were missing or unknown.

177

178 **State Telehealth Parity Laws**

179 Using publicly accessible sources (i.e., state agency websites and national organization
180 websites, such as the Center for Connected Health Policy), we reviewed and collected telehealth
181 parity laws (legislations, regulations, executive orders, and agency policies) in the 50 states and
182 Washington, D.C. in effect from January 1, 2018, to December 31, 2021. To ensure that the
183 study adequately assessed the impact of state telehealth parity laws relevant to preventing,
184 treating, and managing hypertension for individuals enrolled in private insurance, we focused on
185 laws that apply to the provision of primary care services and relevant specialty care. These
186 include cardiology, neurology, medication management, cardiac rehabilitation, telestroke, and
187 chronic disease management.

188 For each state, relevant laws were independently coded by two researchers, and
189 discrepancies in coding were resolved through discussions and consensus. Coding of telehealth
190 coverage and payment parity laws were based on the legal language in each state. A parity law

191 was coded as “payment parity” if it expressly required private payers to reimburse telehealth
192 services at the same rate as an in-person visit (e.g., reimbursement for services provided through
193 telehealth must be equivalent to reimbursement for the same services provided in-person).
194 Similarly, a parity law was coded as “coverage parity” if it contained language expressly
195 requiring private payers to cover the same services for telehealth as if it would have been
196 covered for an in-person visit (e.g., shall provide coverage for services provided via telehealth if
197 it was covered in-person and shall be subject to the same terms and conditions, but coverage
198 parity does not guarantee the same rate of payment).

199 The state law analysis did not assess laws for specialty services not commonly associated
200 with hypertension, stroke, or cardiovascular disease. These include mental health services,
201 hospice, and palliative care. The coded telehealth laws (Appendix Table 3) were then linked to
202 our study sample using state identifiers.

203

204 **Outcomes**

205 The primary outcomes of the study included antihypertensive medication use, measured
206 by the three indicators: 1) average medication possession ratio (MPR) of antihypertensive drugs,
207 2) medication adherence to antihypertensive drugs (defined as $MPR \geq 80\%$), and 3) average
208 number of days of antihypertensive drug supply. Additionally, as secondary outcome measures,
209 we included the number of hypertension-related and cardiovascular disease (CVD)-related
210 telehealth visits.

211 To calculate the average MPR, we estimated the means of the MPRs for the seven
212 antihypertensive therapeutic classes (Appendix Table 2). Each MPR was computed as the ratio
213 of the total days of antihypertensive drug supply to the number of days in each year.¹⁹ A patient

214 was assessed as adherent if the average MPR was $\geq 80\%$.¹⁹ The average days of drug supply
215 referred to the average number of pills of medication supplied per antihypertensive prescription.

216 Telehealth outpatient visits were defined if outpatient visits were telehealth-related using
217 place of service and procedure modifiers (Appendix Table 4). In-person outpatient visits were
218 defined as non-telehealth-related outpatient visits. Telehealth visits can be complementary to in-
219 person care whereby in-person visits might increase follow-up telehealth appointments, or
220 telehealth visits might result in a necessary in-person visit.²⁰ In addition, telehealth can be a
221 substitute to in-person services, such as a telehealth visit substituting an in-person visit during
222 the pandemic.²¹ Therefore, we adjusted for the number of in-person visits when assessing
223 telehealth visits as an outcome, and vice versa. Hypertension- and CVD-related telehealth
224 outpatient visits were identified if telehealth outpatient visits included the respective diagnosis
225 (Appendix Table 1). All outcomes were assessed on a per patient per year basis, providing a
226 comprehensive analysis of hypertension management and telehealth utilization.

227

228 **Statistical Analysis**

229 To estimate the association between telehealth parity laws and hypertension management,
230 we used a generalized difference-in-difference (DID) design with different treatment timing.²²
231 Given that telehealth parity laws were in effect in different states during various time periods, we
232 utilized the different timing of these laws to estimate the generalized DID effects. Within the
233 generalized DID methodology, we used linear regression for average MPR, logistic regression
234 for medication adherence, and negative binomial regression for numbers of days of
235 antihypertensive drug supply; we used exponential hurdle²³ model for number of hypertension-

236 and CVD-related telehealth outpatient visits, since some patients may have zero telehealth visits
237 in a year (e.g., excess zeros in the outcome measure).

238 In sensitivity analyses to test the influence of different model setups on the estimated
239 results we used Probit and linear models for medication adherence. For the number of days of
240 antihypertensive drug supply, we used a zero-inflated negative binomial model. This approach
241 accommodates patients with zero days of drug supply by combining a logit model for zero
242 outcomes and a negative binomial model for the average number of days of drug supply.

243 All models were adjusted for state-fixed effects, year-fixed effects, COVID-19 diagnosis
244 (claims with ICD-10-CM of U07.1), number of in-person visits, age groups (18–34 [reference],
245 35–44, 45–54, and 55–64 years), sex (male [reference], female), urbanicity of residence (urban
246 [reference], rural, per US Census Metropolitan Statistical Area [MSA] designation),¹⁶ and 17
247 Quan-Charlson comorbidities.²⁴ Comorbidities were identified as present if individuals had ≥ 1
248 inpatient admission or ≥ 2 outpatient encounters (≥ 30 days apart) with the corresponding Quan-
249 Charlson ICD-10-CM diagnoses. In addition, state-year level time-varying covariates such as
250 state-year level unemployment rates, GDP per capita, and poverty rates were included in the
251 models. We reported the average marginal effects along with 95% confidence intervals (CI). To
252 account for potential clustering effects, all standard errors were clustered by state. All outcomes
253 are measured on a per patient per year basis, except for the number of telehealth visits, measured
254 as per 1,000 patients per year.

255 Two-tailed p -values < 0.05 were used to indicate statistical significance. All the analyses
256 were conducted using Stata SE 17.0 statistical software (StataCorp, College Station, TX) and
257 SAS version 9.4 (SAS 9.4, Cary, NC. SAS Institute Inc.).

258 **RESULTS**

259 There were 353,220 included individuals (Figure 1). The sociodemographic
260 characteristics of the study cohort at baseline are summarized in Table 1. The average age of
261 patients with hypertension was 49.5 (SD, 7.1) years. Women comprised 45.55% of the cohort,
262 and 84.19% lived in urban areas. Baseline medication adherence fluctuated between 57.54% and
263 60.50% from 2018 to 2021. The most prevalent comorbidities during the lookback period (2016–
264 2017) included diabetes without chronic complications (22.77%), chronic pulmonary disease
265 (8.00%), diabetes with chronic complications (4.83%), any malignancy (3.42%), and renal
266 disease (3.26%). The distribution of the patient cohort in each state is presented in Appendix
267 Table 5.

268 In 2018, one state had a payment parity law, 20 had coverage parity laws, and 6 had both.
269 By 2021, these values had increased to 5 states with payment parity laws, 24 with coverage
270 parity laws, and 16 with both.

271 After controlling for potential confounders, states with a payment parity law saw a
272 statistically significant 0.43 percentage point (95% CI: 0.07 - 0.79) increase in average MPR
273 among individuals with hypertension (Table 2). Furthermore, the payment parity law was
274 significantly associated with a 0.46 percentage point (95% CI: 0.00 - 0.92) increase in the
275 probability of medication adherence and a significant increase in average days of
276 antihypertensive drug supply by 2.14 days (95% CI: 0.11 - 4.17) per patient per antihypertensive
277 prescription.

278 Coverage parity laws were not significantly associated with average MPR or medication
279 adherence, but were associated with a significant increase in average days of antihypertensive
280 drug supply by 2.13 days (95% CI: 0.19 - 4.07) per patient per antihypertensive prescription.

281 Payment parity laws were associated with a significant increase in the number of
282 hypertension-related telehealth visits by 2.61 visits per 1,000 patients (95% CI: 0.99 - 4.23) and
283 CVD-related telehealth visits by 0.92 visits per 1,000 patients (95% CI: 0.23 - 1.61) (Appendix
284 Table 6). On the other hand, coverage parity laws did not show a statistically significant
285 association with the number of telehealth visits (Appendix Table 7).

286 In sensitivity analyses, we tested different model setups (Probit and linear regression) for
287 the medication adherence measure, and the results remained largely unchanged (Appendix Table
288 8). Moreover, when using the zero-inflated negative binomial model for the average days of drug
289 supply, the association with state payment parity was positive, but not statistically significant
290 (Appendix Table 9).

291

292 **DISCUSSION**

293 This study comprehensively assessed the potential impact of telehealth parity laws on
294 hypertension management before and during the COVID-19 pandemic among private payers
295 across the 50 states and DC. We distinguished between payment parity and coverage parity, as
296 these different types of parity laws could have differential impact on patient access and behavior.
297 Interestingly, the results revealed that state payment parity laws for hypertension-related
298 telehealth services were significantly associated with increased average MPR, adherence to
299 antihypertensive medications, and average days of drug supply. However, coverage parity laws
300 were not found to be significantly associated with average MPR or medication adherence, but
301 significantly associated with increased average days of drug supply. Furthermore, both types of
302 parity laws did not significantly influence the numbers of hypertension-related telehealth visits or

303 in-person visits during the study period. These findings remained robust after using alternative
304 models in sensitivity analyses.

305 Applying a quasi-experimental generalized DID design, one key finding of our study was
306 that telehealth payment parity laws were associated with significant improvements in medication
307 adherence among patients with hypertension. It is possible that telehealth visits facilitated
308 hypertension management by improving continuity of care, such as by alleviating patient
309 concerns about exposure to SARS-CoV-2, the virus that causes COVID-19, during in-person
310 office visits. In a recent study, Patel et al. (2020) estimated that the overall volume of care for
311 hypertension dropped by 23.0% at the outset of the pandemic.²⁵ Delayed care could lead to
312 worsened outcomes for patients with poorly controlled hypertension, including heart attacks,
313 coronary heart disease, strokes, and kidney damage.²⁶ Consequently, telehealth use surged to
314 ensure patient access to medical care without compromising patient and clinician safety. Though
315 the marginal effect of 0.46 percentage point increase in the probability of medication adherence
316 we observed seemed modest, considering that approximately 48 million individuals aged 20–64
317 have high blood pressure and are currently taking an antihypertensive medication, of whom
318 66.0% are covered by private insurance (as per NHANES 2017–2018 data),²⁷ nationwide
319 adoption of telehealth payment parity laws across all states could potentially result in
320 approximately 145,728 more individuals achieving adherence to antihypertensive medications
321 (MPR \geq 80%). State telehealth payment parity laws were associated with immediate and positive
322 impacts on populations affected by hypertension during the COVID-19 pandemic, especially
323 given that telehealth usage has been associated with significant improvements in blood pressure
324 control.²⁸

325 Previous evidence-based studies suggest that an effective telehealth model for
326 hypertension management should incorporate self-measured blood pressure monitoring or
327 remote patient monitoring (RPM) that requires patients to record blood pressure outside of
328 clinical settings and share the data with their clinicians.²⁹ Another essential component of a
329 telehealth visit includes consultations on the proper use of antihypertensive medications and
330 adherence to medication regimens, and health education regarding lifestyle changes, often
331 delivered through Internet video teleconferences on mobile devices.² This approach may be
332 combined with team-based care to provide this array of follow up services by a multidisciplinary
333 team including physicians, nurses, health coaches, and pharmacists.³⁰ But this combined
334 approach may not always be practical, due to challenges such as patient access to digital
335 platforms, reliable internet connection, and availability of compatible devices for vital sign
336 measurement and transmission.³¹⁻³³ To address these limitations, more simplified versions of
337 telehealth, such as audio-only phone-based services, text messaging (SMS), or emails have also
338 emerged as alternatives for communication that may still support treatment adherence and
339 symptom surveillance.³⁴⁻³⁶ Some states have passed laws allowing reimbursement for audio-only
340 services, primarily for the state Medicaid program, catering to the needs of patients with lower
341 incomes who might lack smartphones or digital connectivity.^{32,34} Future studies could explore
342 the influence of these laws on hypertension management.

343 We found that telehealth coverage parity laws were significantly associated with an
344 increase in the average days of antihypertensive drug supply, but did not improve medication
345 adherence. This could, in part, be attributed to telehealth coverage parity solely confirming
346 insurance coverage without ensuring consistent reimbursement structures. Telehealth coverage
347 parity alone can result in patients incurring higher out-of-pocket costs for telehealth services.

348 Another possibility is that coverage parity laws may influence clinician behavior. For instance, if
349 the reimbursement rates for telehealth are lower, healthcare systems or clinicians may reduce the
350 number of telehealth appointments offered and extend the duration of prescriptions for patients.

351 As shown in our study, more states adopted telehealth coverage parity or both parity laws
352 rather than only payment parity laws. A recent review provides a comparative analysis of state-
353 by-state adoption of telehealth parity, highlighting the need for alternative payment models,
354 assessing resource utilization, and considering costs linked to virtual care.⁸ Certainly, looking
355 beyond the pandemic, integrating telehealth into hypertension management without increasing
356 utilization of telehealth may demand innovative payment models and care quality metrics.³⁷

357 In the present study, we found a significant association between telehealth payment parity
358 laws and the number of hypertension- and CVD-related telehealth visits. This finding was
359 consistent with previous research. For example, a study analyzing 2010–2015 MarketScan®
360 commercial claims data observed significant increases in outpatient telehealth visits in states
361 with parity laws.⁶ Another study demonstrated enrollees in states with private payer telehealth
362 laws were more likely to receive video assessments.⁷ However, our study did not find that
363 telehealth coverage laws alone were significantly associated with the number of telehealth visits.
364 Compared with prior studies, our study specifically examined the impact of these laws during the
365 pandemic period, and focused on the laws relevant to hypertension and CVD management.
366 These methodological and contextual differences may account for the differences in our
367 findings.²⁵

368 There are several key strengths of this study. First, unlike prior research that did not
369 distinguish between the effects of payment parity laws and coverage parity laws, we contributed
370 to the literature by evaluating the net impact of these two types of laws individually and teasing

371 out their effects separately while providing a more comprehensive understanding of the impact
372 of state laws governing private payer reimbursements for telehealth services. Second, while
373 previous parity law studies predominantly centered around mental health services, our focus was
374 on relevant laws affecting hypertension management and control, filling a critical research gap.
375 Third, the variation in state policies across different years posed a challenge to the traditional
376 DID analysis; thus, we used a generalized DID approach, which is a more advanced and flexible
377 method to evaluate policy impacts.

378 There are a few limitations in our study. First, for the state law analysis, we identified and
379 collected telehealth parity laws from secondary sources. Some relevant laws may have been
380 missed because they were unavailable, used vague language, or were missing key information
381 (such as legal citations). In instances where effective dates were missing, the dates were
382 represented by a proxy date using January 1 of the respective year. Nevertheless, we believe that
383 this should not significantly affect our analysis. For instance, if the law was implemented at the
384 end of the year, our analysis was based on the data for that specific year, which may even make
385 our estimates conservative. Second, some states might have implemented temporary telehealth
386 COVID-19 emergency policies that were difficult to search for online, or may have expired
387 during the study period. However, we did not include these policies in the treatment group and
388 focused our analysis on permanent laws rather than temporary policies. Third, apart from
389 telehealth parity laws, another important regulatory aspect at the state level is licensure
390 requirements,³⁸ which can potentially influence the impact of parity laws on hypertension
391 management. Some states have adopted interstate telemedicine laws, while others mandate
392 registration for such practices.^{3,8,9} Language barriers and costs of telehealth infrastructure may
393 hinder implementation. Additionally, varying state policies impact the rates of hospital telehealth

394 adoption,³ and private payer reimbursement policies correlating with higher adoption rates. None
395 of these factors were considered in the current analysis, as they fell outside the scope of the
396 study. Fourth, although the MarketScan® commercial claims database provides a national
397 sample that has comprehensive geographical representation covering all 50 states and D.C., there
398 might be variations in the study population selected from different states. Nevertheless, this
399 limitation has been mitigated through the adjustment for state fixed effects and state-level time-
400 varying variables. Fifth, we did not assess whether participants relocated from one state to
401 another during the study period. Since our sample selection criteria required continuous
402 enrollment of participants during the study period, participants who moved were likely excluded
403 from our study cohort.

404

405 **CONCLUSION**

406 Our findings suggest that state telehealth payment parity laws may be significantly
407 associated with hypertension treatment based on increased related telehealth visits and
408 medication adherence. However, coverage parity laws alone do not have a significant association
409 with telehealth services or medication adherence. Future studies could assess the associations of
410 state telehealth laws for public payers and uninsured groups, as well as how licensure
411 requirements are associated with hypertension management. Given that hypertension affects
412 roughly half of the adult population, our study holds significant implications for the evolving
413 U.S. healthcare system in the digital age.³⁹ Our results offer insights into the potential role of
414 telehealth parity laws for private payers in facilitating hypertension management.

415 **REFERENCES**


416
417

- 418 1. Mabeza RMS, Maynard K and Tarn DM. Influence of synchronous primary care
419 telemedicine versus in-person visits on diabetes, hypertension, and hyperlipidemia outcomes: a
420 systematic review. *BMC primary care*. 2022;23:1-10.
- 421 2. Omboni S, McManus RJ, Bosworth HB, Chappell LC, Green BB, Kario K, Logan AG,
422 Magid DJ, Mckinstry B and Margolis KL. Evidence and recommendations on the use of
423 telemedicine for the management of arterial hypertension: an international expert position
424 paper. *Hypertension*. 2020;76:1368-1383.
- 425 3. Adler-Milstein J, Kvedar J and Bates DW. Telehealth among US hospitals: several
426 factors, including state reimbursement and licensure policies, influence adoption. *Health Affairs*.
427 2014;33:207-215.
- 428 4. Nicol Turner Lee JK and Roberts J. Removing regulatory barriers to telehealth before
429 and after COVID-19. *Brookings Institution*. 2020.
- 430 5. Faget KY, Boubker, J. Legal considerations. In *Emerging Practices in Telehealth: Academic Press*;
431 2023: 77-96.
- 432 6. Harvey JB, Valenta S, Simpson K, Lyles M and McElligott J. Utilization of outpatient
433 telehealth services in parity and nonparity states 2010–2015. *Telemedicine and e-Health*.
434 2019;25:132-136.
- 435 7. Lee H and Singh GK. The Impact of Telemedicine Parity Requirements on Telehealth
436 Utilization in the United States During the COVID-19 Pandemic. *Journal of Public Health*
437 *Management and Practice*. 2023;29:E147-E156.
- 438 8. Khara N, Knoedler M, Meier SK, TerKonda S, Williams RD, Wittich CM, Coffey JD and
439 Demaerschalk BM. Payment and Coverage Parity for Virtual Care and In-Person Care: How Do
440 We Get There? *Telemedicine Reports*. 2023;4:100-108.
- 441 9. Totten AM, Hansen RN, Wagner J, Stillman L, Ivlev I, Davis-O'Reilly C, Towle C,
442 Erickson JM, Erten-Lyons D and Fu R. Telehealth for acute and chronic care consultations.
443 2019.
- 444 10. Center for Connected Health Policy. Parity requirements for private payer telehealth
445 services. 2023;2023.
- 446 11. Gliske K, Berry KR, Ballard J, Evans-Chase M, Solomon PL and Fenkel C. Mental health
447 outcomes for youths with public versus private health insurance attending a telehealth intensive
448 outpatient program: quality improvement analysis. *JMIR Formative Research*. 2022;6:e41721.
- 449 12. Amill-Rosario A, Rose R and dosReis S. Impact of Private Payer Policies on the
450 Transition to Telemental Health Care Among Privately Insured Patients with Mental Health
451 Disorders. *Telemedicine and e-Health*. 2023.
- 452 13. Andersen RM, Rice TH and Kominski GF. *Changing the US health care system: Key*
453 *issues in health services policy and management*. John Wiley & Sons; 2011.
- 454 14. Granger BB and Bosworth H. Medication adherence: emerging use of technology.
455 *Current opinion in cardiology*. 2011;26:279.
- 456 15. Kini V and Ho PM. Interventions to improve medication adherence: a review. *Jama*.
457 2018;320:2461-2473.
- 458 16. Merative MarketScan® Research Databases.
459 <https://marketscan.truvenhealth.com/marketscanportal>. Accessed April 14, 2023.
- 460 17. Kuklina EV, Tong X, Bansil P, George MG and Callaghan WM. Trends in pregnancy
461 hospitalizations that included a stroke in the United States from 1994 to 2007: reasons for
462 concern? *Stroke*. 2011;42:2564-2570.

- 463 18. Lee JS, MacLeod KE, Kuklina EV, Tong X and Jackson SL. Social Determinants of
464 Health–Related Z Codes and Health Care Among Patients With Hypertension. *AJPM Focus*.
465 2023;2:100089.
- 466 19. Canfield SL, Zuckerman A, Anguiano RH, Jolly JA, DeClercq J, Wascher M, Choi L,
467 Knox S and Mitchell DG. Navigating the wild west of medication adherence reporting in
468 specialty pharmacy. *J Manag Care Spec Pharm*. 2019;25:1073-1077.
- 469 20. Chao GF, Li KY, Zhu Z, McCullough J, Thompson M, Claflin J, Fliegner M, Steppe E,
470 Ryan A and Ellimoottil C. Use of telehealth by surgical specialties during the COVID-19
471 pandemic. *JAMA surgery*. 2021;156:620-626.
- 472 21. Cao Y, Chen D and Smith M. Use telehealth as needed: telehealth substitutes in-person
473 primary care and associates with the changes in unplanned events and follow-up visits. *BMC*
474 *Health Services Research*. 2023;23:426.
- 475 22. Richardson DB, Ye T and Tchetgen Tchetgen EJ. Generalized Difference-in-Differences.
476 *Epidemiology*. 2023;34:167-174.
- 477 23. Cragg JG. Some statistical models for limited dependent variables with application to the
478 demand for durable goods. *Econometrica: journal of the Econometric Society*. 1971:829-844.
- 479 24. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J-C, Saunders LD, Beck
480 CA, Feasby TE and Ghali WA. Coding algorithms for defining comorbidities in ICD-9-CM and
481 ICD-10 administrative data. *Med Care*. 2005;1130-1139.
- 482 25. Patel SY, Mehrotra A, Huskamp HA, Uscher-Pines L, Ganguli I and Barnett ML.
483 Variation in telemedicine use and outpatient care during the COVID-19 pandemic in the United
484 States: study examines variation in total US outpatient visits and telemedicine use across
485 patient demographics, specialties, and conditions during the COVID-19 pandemic. *Health Aff*
486 *(Millwood)*. 2021;40:349-358.
- 487 26. CDC. National Center for Chronic Disease Prevention and Health Promotion, Division for
488 Heart Disease and Stroke Prevention. Facts About Hypertension. 2023.
- 489 27. Rana J, Oldroyd J, Islam MM, Tarazona-Meza CE and Islam RM. Prevalence of
490 hypertension and controlled hypertension among United States adults: evidence from NHANES
491 2017-18 survey. *International Journal of Cardiology Hypertension*. 2020;7:100061.
- 492 28. Jackson TN, Sreedhara M, Bostic M, Spafford M, Popat S, Lowe Beasley K, Jordan J
493 and Ahn R. Telehealth Use to Address Cardiovascular Disease and Hypertension in the United
494 States: A Systematic Review and Meta-Analysis, 2011–2021. *Telemedicine Reports*. 2023;4:67-
495 86.
- 496 29. Kario K. Management of hypertension in the digital era: small wearable monitoring
497 devices for remote blood pressure monitoring. *Hypertension*. 2020;76:640-650.
- 498 30. Jacob V, Chattopadhyay SK, Proia KK, Hopkins DP, Reynolds J, Thota AB, Jones CD,
499 Lackland DT, Rask KJ and Pronk NP. Economics of self-measured blood pressure monitoring: a
500 community guide systematic review. *American journal of preventive medicine*. 2017;53:e105-
501 e113.
- 502 31. Zhang D, Shi L, Han X, Li Y, Jalajel NA, Patel S, Chen Z, Chen L, Wen M and Li H.
503 Disparities in telehealth utilization during the COVID-19 pandemic: Findings from a nationally
504 representative survey in the United States. *Journal of Telemedicine and Telecare*.
505 2021:1357633X211051677.
- 506 32. Kuziemy C, Hunter I, Udayasankaran JG, Ranatunga P, Kulatunga G, John S, John
507 O, Flórez-Arango JF, Ito M and Ho K. Telehealth as a means of enabling health equity.
508 *Yearbook of Medical Informatics*. 2022;31:060-066.
- 509 33. Omboni S, Padwal RS, Alessa T, Benczúr B, Green BB, Hubbard I, Kario K, Khan NA,
510 Konradi A and Logan AG. The worldwide impact of telemedicine during COVID-19: current
511 evidence and recommendations for the future. *Connected health*. 2022;1:7.
- 512 34. Odukoya EJ, Andino J, Ng S, Steppe E and Ellimoottil C. Predictors of Video versus
513 Audio-Only Telehealth Use among Urological Patients. *Urology practice*. 2022;9:198-204.

- 514 35. Tam HL, Wong EML, Cheung K and Chung SF. Effectiveness of text messaging
515 interventions on blood pressure control among patients with hypertension: systematic review of
516 randomized controlled trials. *JMIR mHealth and uHealth*. 2021;9:e24527.
- 517 36. Berrouiguet S, Baca-García E, Brandt S, Walter M and Courtet P. Fundamentals for
518 future mobile-health (mHealth): a systematic review of mobile phone and web-based text
519 messaging in mental health. *Journal of medical Internet research*. 2016;18:e135.
- 520 37. Dinesen B, Nonnecke B, Lindeman D, Toft E, Kidholm K, Jethwani K, Young HM,
521 Spindler H, Oestergaard CU and Southard JA. Personalized telehealth in the future: a global
522 research agenda. *Journal of medical Internet research*. 2016;18:e53.
- 523 38. Adams AJ. Facilitating multistate pharmacy practice: streamlining continuing pharmacy
524 education requirements. *Journal of the American Pharmacists Association*. 2023;63:731-735.
- 525 39. Chobufo MD, Gayam V, Soluny J, Rahman EU, Enoru S, Foryoung JB, Agbor VN,
526 Dufresne A and Nfor T. Prevalence and control rates of hypertension in the USA: 2017–2018.
527 *International Journal of Cardiology Hypertension*. 2020;6:100044.
528

529 **Figure 1. Study sample selection of patients with hypertension, MarketScan® Commercial**
530 **Claims and Encounters Database, 2016–2021.**



Abbreviation: ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification

^a Age was calculated as of December 31, 2021, the ending period of the sample period, to exclude patients diagnosed with AF before aged 65, but became 65+ during the sample periods.

^b Of the 100,515 patients, 100,382 had unknown state information, 7 had Puerto Rico state information, and 126 had missing state information.

576 **Table 1. Baseline Characteristics of patients with hypertension in MarketScan®**
 577 **Commercial Claims and Encounters Database, 2016–2021.**
 578

| | N=353,220 |
|-------------------------------------------------------------|------------------|
| Baseline Characteristics | |
| Age, mean (SD) | 49.5 (7.1) |
| Age groups, n (%) | |
| 18–34 | 14,695 (4.16%) |
| 35–44 | 64,651 (18.30%) |
| 45–54 | 168,706 (47.76%) |
| 55–64 | 105,168 (29.77%) |
| Female, n (%) | 160,903 (45.55%) |
| Urban Residency, n (%) | 297,364 (84.19%) |
| Census regions, n (%) | |
| Northeast | 48,266 (13.66%) |
| Midwest | 84,284 (23.86%) |
| South | 186,515 (52.80%) |
| West | 33,495 (9.48%) |
| Baseline medication adherence ^a, n (%) | |
| Year 2018 | 205,869 (58.28%) |
| Year 2019 | 203,227 (57.54%) |
| Year 2020 | 213,715 (60.50%) |
| Year 2021 | 209,405 (59.28%) |
| Comorbidities in lookback periods (2016–2017), n (%) | |
| Myocardial infarction | 5,995 (1.70%) |
| Congestive heart failure | 8,521 (2.41%) |
| Cerebrovascular | 6,841 (1.94%) |
| Peripheral vascular | 2,708 (0.77%) |
| Dementia | 100 (0.03%) |
| Chronic pulmonary disease | 28,266 (8.00%) |
| Rheumatic disease | 5,929 (1.68%) |
| Peptic ulcer disease | 1,286 (0.36%) |
| Mild liver disease | 9,995 (2.83%) |
| Diabetes without chronic complication | 80,424 (22.77%) |
| Diabetes with chronic complication | 17,067 (4.83%) |
| Hemiplegia or paraplegia | 1,137 (0.32%) |
| Renal disease | 11,517 (3.26%) |
| Any malignancy | 12,081 (3.42%) |
| Moderate or severe liver disease | 516 (0.15%) |
| Metastatic solid tumor | 1,137 (0.32%) |
| AIDS/HIV | 1,075 (0.30%) |

579
 580 ^a Medication adherence was defined as a dummy indicator, where = 1 if the average medication
 581 possession ratio of the seven antihypertensive therapeutic classes is $\geq 80\%$, otherwise = 0.

582 **Table 2. The association of telehealth payment parity laws with medication adherence,**
 583 **medication possession ratios, and average number of drug supply per antihypertensive**
 584 **drug, 2018–2021.^a**
 585

| | Average Medication Possession Ratios | Medication Adherence (%)^b | Average days of drug supply |
|-----------------------------------|---------------------------------------------|---------------------------------------------|--------------------------------------|
| Payment parity | 0.43* (0.07 - 0.79) | 0.46* (0.00 - 0.92) | 2.14* (0.11 - 4.17) |
| Covariates | | | |
| COVID-19 diagnosis | -1.69*** (-1.95 - -1.42) | -3.57*** (-4.02 - -3.11) | -2.19*** (-3.12 - -1.27) |
| Number of in-person visits | 0.05*** (0.04 - 0.07) | 0.00 (-0.00 - 0.00) | -0.15*** (-0.17 - -0.13) |
| Aged 18–34 [reference] | | | |
| Aged 35–44 | 9.83*** (9.09 - 10.57) | 9.33*** (8.56 - 10.1) | 16.96*** (15.69 - 18.23) |
| Aged 45–54 | 17.07*** (16.33 - 17.82) | 17.90*** (17.10 - 18.60) | 27.04*** (25.49 - 28.59) |
| Aged 55–64 | 21.21*** (20.31 - 22.11) | 23.90*** (23.00 - 24.70) | 31.55*** (29.40 - 33.70) |
| Male [reference] | | | |
| Female | -2.93*** (-3.25 - -2.60) | -3.95*** (-4.36 - -3.54) | -9.20*** (-10.16 - -8.24) |
| Rural [reference] | | | |
| Urban | 0.24 (-0.34 - 0.81) | -0.41 (-1.09 - 0.269) | 6.98*** (3.50 - 10.47) |
| Comorbidities | | | |
| Myocardial infarction | -1.57*** (-2.41 - -0.73) | -0.81 (-1.92 - 0.309) | -18.46*** (-20.01 - -16.90) |
| Congestive heart failure | -1.24*** (-1.85 - -0.63) | -2.88*** (-3.71 - -2.05) | -23.52*** (-25.13 - -21.90) |
| Cerebrovascular | -0.75* (-1.38 - -0.11) | -0.857 (-1.73 - 0.01) | -10.18*** (-11.34 - -9.013) |
| Peripheral vascular | -3.03*** (-4.39 - -1.66) | -2.97*** (-4.47 - -1.46) | -13.01*** (-15.53 - -10.49) |
| Dementia | -11.15** (-17.83 - -4.47) | -10.00** (-16.70 - -3.33) | -33.00*** (-44.90 - -21.10) |
| Chronic pulmonary disease | -2.71*** (-3.16 - -2.25) | -3.46*** (-4.00 - -2.93) | -6.38*** (-7.26 - -5.49) |
| Rheumatic disease | -1.57*** (-2.41 - -0.74) | -2.26*** (-3.29 - -1.22) | -4.50*** (-6.33 - -2.66) |
| Peptic ulcer disease | -7.84*** (-9.18 - -6.49) | -9.36*** (-11.00 - -7.70) | -16.52*** (-19.95 - -13.09) |

| | | | |
|----------------------------------------------|------------------------------|-----------------------------|--------------------------------|
| Mild liver disease | -2.79*** (-3.51 - -2.06) | -2.42*** (-3.36 - -1.48) | -6.12*** (-7.90 - -4.34) |
| Diabetes without chronic complication | 1.60*** (1.34 - 1.87) | 1.46*** (1.07 - 1.85) | 8.56*** (7.73 - 9.39) |
| Diabetes with chronic complication | -1.37*** (-1.83 - -0.91) | -2.04*** (-2.67 - -1.42) | -1.64*** (-2.39 - -0.88) |
| Hemiplegia or paraplegia | -3.63** (-6.32 - -0.93) | -2.73* (-5.18 - -0.28) | -13.37*** (-19.09 - -7.64) |
| Renal disease | -0.24 (-0.84 - 0.35) | -2.01*** (-2.72 - -1.31) | -14.09*** (-15.91 - -12.28) |
| Any malignancy | 0.72 (-0.01 - 1.46) | 1.66*** (0.85 - 2.47) | -0.11 (-1.49 - 1.27) |
| Moderate or severe liver disease | -7.14*** (-11.07 - -3.20) | -9.99*** (-14.0 - -6.01) | -36.23*** (-43.18 - -29.29) |
| Metastatic solid tumor | -7.11*** (-8.63 - -5.59) | -7.11*** (-8.99 - -5.22) | -13.71*** (-18.75 - -8.68) |
| AIDS/HIV | 2.35** (0.62 - 4.07) | 2.94*** (1.19 - 4.70) | -7.882*** (-11.78 - -3.98) |
| State-year level covariates | | | |
| Unemployment rates | 0.19* (0.03 - 0.35) | 0.32** (0.08 - 0.56) | -0.12 (-0.80 - 0.56) |
| GDP per capita | -0.00 (-0.00 - 0.00) | -0.00 (-0.00 - 0.00) | -0.00 (-0.00 - 0.00) |
| Poverty rates | 0.01 (-0.11 - 0.13) | 0.00 (-0.11 - 0.18) | -0.17 (-0.41 - 0.07) |
| | | | |
| State fixed effects | Yes | Yes | Yes |
| Year fixed effects | Yes | Yes | Yes |
| Observations | 353,220 | 353,220 | 353,220 |

586

587 ^a A logistic regression was used for medication adherence. A linear regression was used for the average medication
588 possession ratios. A negative binomial regression was used for the average number of days of antihypertensive drug
589 supply. All models were adjusted for state-fixed effects, year-fixed effects, COVID-19 diagnosis, number of in-
590 person visits, patients' age groups, sex, urbanicity of residence, comorbidities, and state-year level time-varying
591 covariates (state-year level unemployment rates, GDP per capita, and poverty rates). Average marginal effects with
592 95% CI (in parentheses) were reported. All standard errors were clustered by states.

593 ^b Medication adherence was defined as a dummy indicator, where = 1 if the average medication possession ratio of
594 the seven antihypertensive therapeutic classes is $\geq 80\%$, otherwise = 0.

595

596 **Table 3. The association of telehealth coverage parity laws with medication adherence,**
 597 **medication possession ratios, and average number of drug supply per antihypertensive**
 598 **drug, 2018–2021.^a**
 599

| | Average Medication Possession Ratios (%) | Medication Adherence (%)^b | Average days of drug supply |
|-----------------------------------|-------------------------------------------------|---------------------------------------------|--------------------------------------|
| Coverage parity | 0.26 (-0.14 - 0.66) | 0.10 (-0.36 - 0.56) | 2.13* (0.19 - 4.07) |
| Covariates | | | |
| COVID-19 diagnosis | -1.69*** (-1.96 - -1.42) | -3.57*** (-4.03 - -3.11) | -2.20*** (-3.13 - -1.27) |
| Number of in-person visits | 0.05*** (0.04 - 0.07) | -0.00 (-0.02 - 0.02) | -0.15*** (-0.17 - -0.13) |
| Aged 18–34 [reference] | | | |
| Aged 35–44 | 9.83*** (9.09 - 10.57) | 9.33*** (8.56 - 10.10) | 16.96*** (15.69 - 18.23) |
| Aged 45–54 | 17.07*** (16.33 - 17.82) | 17.90*** (17.1 - 18.60) | 27.04*** (25.49 - 28.59) |
| Aged 55–64 | 21.21*** (20.31 - 22.11) | 23.90*** (23.00 - 24.70) | 31.55*** (29.41 - 33.70) |
| Male [reference] | | | |
| Female | -2.93*** (-3.25 - -2.60) | -3.95*** (-4.36 - -3.54) | -9.20*** (-10.16 - -8.24) |
| Rural [reference] | | | |
| Urban | 0.24 (-0.34 - 0.81) | -0.41 (-1.09 - 0.27) | 6.98*** (3.50 - 10.46) |
| Comorbidities | | | |
| Myocardial infarction | -1.57*** (-2.41 - -0.73) | -0.81 (-1.92 - 0.31) | -18.46*** (-20.01 - -16.90) |
| Congestive heart failure | -1.24*** (-1.85 - -0.63) | -2.88*** (-3.71 - -2.05) | -23.52*** (-25.13 - -21.90) |
| Cerebrovascular | -0.75* (-1.38 - -0.11) | -0.86 (-1.73 - 0.01) | -10.18*** (-11.34 - -9.012) |
| Peripheral vascular | -3.03*** (-4.39 - -1.66) | -2.97*** (-4.47 - -1.46) | -13.01*** (-15.52 - -10.49) |
| Dementia | -11.15** (-17.83 - -4.47) | -10.00** (-16.70 - -3.33) | -33.01*** (-44.90 - -21.11) |
| Chronic pulmonary disease | -2.71*** (-3.16 - -2.25) | -3.46*** (-4.00 - -2.93) | -6.37*** (-7.26 - -5.49) |
| Rheumatic disease | -1.57*** (-2.41 - -0.74) | -2.26*** (-3.29 - -1.22) | -4.50*** (-6.33 - -2.66) |

| | | | |
|----------------------------------------------|------------------------------|------------------------------|--------------------------------|
| Peptic ulcer disease | -7.84*** (-9.18 - -6.49) | -9.36*** (-11.0 - -7.70) | -16.52*** (-19.95 - -13.08) |
| Mild liver disease | -2.79*** (-3.51 - -2.06) | -2.42*** (-3.36 - -1.48) | -6.12*** (-7.90 - -4.34) |
| Diabetes without chronic complication | 1.60*** (1.34 - 1.87) | 1.46*** (1.07 - 1.85) | 8.56*** (7.73 - 9.39) |
| Diabetes with chronic complication | -1.37*** (-1.83 - -0.91) | -2.04*** (-2.67 - -1.42) | -1.63*** (-2.39 - -0.88) |
| Hemiplegia or paraplegia | -3.63** (-6.32 - -0.93) | -2.73* (-5.18 - -0.28) | -13.36*** (-19.09 - -7.64) |
| Renal disease | -0.24 (-0.84 - 0.35) | -2.01*** (-2.72 - -1.31) | -14.09*** (-15.91 - -12.28) |
| Any malignancy | 0.72 (-0.01 - 1.46) | 1.66*** (0.846 - 2.47) | -0.11 (-1.49 - 1.27) |
| Moderate or severe liver disease | -7.14*** (-11.07 - -3.20) | -9.99*** (-14.00 - -6.01) | -36.23*** (-43.18 - -29.29) |
| Metastatic solid tumor | -7.11*** (-8.63 - -5.59) | -7.11*** (-8.99 - -5.22) | -13.71*** (-18.75 - -8.68) |
| AIDS/HIV | 2.35** (0.62 - 4.07) | 2.94*** (1.19 - 4.70) | -7.88*** (-11.78 - -3.982) |
| State-year level covariates | | | |
| Unemployment rates | 0.19* (0.03 - 0.36) | 0.30* (0.05 - 0.55) | -0.05 (-0.71 - 0.61) |
| GDP per capita | -0.00 (-0.00 - 0.00) | -0.00 (-0.00 - 0.00) | -0.00 (-0.00 - 0.00) |
| Poverty rates | -0.00 (-0.11 - 0.11) | 0.03 (-0.12 - 0.18) | -0.26* (-0.49 - -0.03) |
| State fixed effects | Yes | Yes | Yes |
| Year fixed effects | Yes | Yes | Yes |
| Observations | 353,220 | 353,220 | 353,220 |

600 ^a A logistic regression was used for medication adherence. A linear regression was used for the average medication
601 possession ratios. A negative binomial regression was used for the average number of days of antihypertensive drug
602 supply. All models were adjusted for state-fixed effects, year-fixed effects, COVID-19 diagnosis, number of in-
603 person visits, patients' age groups, sex, urbanicity of residence, comorbidities, and state-year level time-varying
604 covariates (state-year level unemployment rates, GDP per capita, and poverty rates). Average marginal effects with
605 95% CI (in parentheses) were reported. All standard errors were clustered by states.

606 ^b Medication adherence was defined as a dummy indicator, where = 1 if the average medication possession ratio of
607 the seven antihypertensive therapeutic classes is $\geq 80\%$, otherwise = 0.

Appendix Table 1. ICD-10-CM diagnosis codes for hypertension and ICD-10-CM diagnosis, procedure, and DRG codes for pregnancy

| | ICD-10-CM | DRG | ICD-10-PCS |
|-------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|
| Hypertension | I10-I15 | NA | NA |
| Cardiovascular disease | I00-I78 | NA | NA |
| Pregnancy | O00-O99, O9A1-O9A5, Z33, Z34, Z36, Z37, Z3201, Z322, Z39, F53, A34 | 765, 766, 767, 768, 769, 770, 771, 772, 773, 775, 776, 777, 779, 780, 781, 782 | 10A0, 10D00Z0, 10D00Z1, 10D00Z2, 10D07Z3, 10D07Z4, 10D07Z5, 10D07Z6, 10D07Z7, 10D07Z8, 10E0XZZ |

Abbreviations: DRG, diagnosis-related group; ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification; ICD-10-PCS, International Classification of Diseases, Tenth Revision, Procedure Coding System

NA indicates not available.

Appendix Table 2. Antihypertensives by therapeutic class

| Therapeutic Class | Antihypertensive Medications |
|------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ACE inhibitor | Benazepril Bepridil Captopril Enalapril Fosinopril Lisinopril Moexipril Perindopril Quinapril Ramipril Trandolapril |
| Angiotensin receptor blocker | Azilsartan Candesartan Eprosartan Irbesartan Losartan Olmesartan Telmisartan Valsartan |
| Beta blocker | Acebutolol Atenolol Betaxolol Bisoprolol Carvedilol Labetalol Metoprolol succinate Metoprolol tartrate Nadolol Nebivolol Pindolol Propranolol |
| Calcium channel blocker | Amlodipine Diltiazem Felodipine Isradipine Levamlodipine Nicardipine Nifedipine Nisoldipine Verapamil |
| Diuretic | Amiloride Bumetanide Chlorothiazide Chlorthalidone |

| | |
|---------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | <p>Furosemide Hydrochlorothiazide Indapamide Methyclothiazide Metolazone Toremide Triamterene</p> |
| Other antihypertensives | <p>Clonidine Doxazosin Eplerenone Guanabenz Guanfacine Hydralazine Methyldopa Minoxidil Prazosin Spironolactone Terazosin</p> |
| Renin-angiotensin system antagonists ^a | <p>Aliskiren Azilsartan Benazepril Bepridil Candesartan Captopril Enalapril Eprosartan Fosinopril Irbesartan Lisinopril Losartan Moexipril Olmesartan Perindopril Quinapril Ramipril Telmisartan Trandolapril Valsartan</p> |

^a Renin-angiotensin system antagonists are a composite therapeutic class consisting of ACE inhibitors, angiotensin receptor blockers, and aliskiren.

Appendix Table 3. State telehealth payment and coverage parity laws in effect January 1, 2018 – December 31, 2021

| State | 2018 | 2019 | 2020 | 2021 |
|-----------------------------|-------------|-------------|-------------|-------------|
| Alabama | None | None | None | None |
| Alaska | None | None | Coverage | Coverage |
| Arizona | Coverage | Coverage | Coverage | Both |
| Arkansas | Both | Both | Both | Both |
| California | None | None | None | Both |
| Colorado | Coverage | Coverage | Both | Both |
| Connecticut | Coverage | Coverage | Coverage | Both |
| Delaware | Both | Payment | Both | Payment |
| District of Columbia | Coverage | Coverage | Coverage | Coverage |
| Florida | None | None | None | None |
| Georgia | None | None | Both | Both |
| Hawaii | Payment | Payment | Payment | Payment |
| Idaho | None | None | None | None |
| Illinois | None | None | None | Both |
| Indiana | Coverage | Coverage | Coverage | Coverage |
| Iowa | None | Coverage | Coverage | Coverage |
| Kansas | None | None | None | None |
| Kentucky | None | Both | Both | Both |
| Louisiana | None | None | None | Coverage |
| Maine | Coverage | Coverage | Coverage | Coverage |
| Maryland | None | None | Coverage | Both |
| Massachusetts | Coverage | Coverage | Coverage | Coverage |
| Michigan | None | None | None | None |
| Minnesota | Both | Both | Both | Coverage |
| Mississippi | Coverage | Coverage | Coverage | Both |
| Missouri | Both | Both | Both | Both |
| Montana | Coverage | Coverage | Coverage | Coverage |
| Nebraska | Coverage | Coverage | Coverage | Coverage |
| Nevada | Coverage | Coverage | Coverage | Both |
| New Hampshire | Coverage | Coverage | Both | Both |
| New Jersey | Both | Both | Both | Both |
| New Mexico | Coverage | Both | Both | Coverage |
| New York | Coverage | Coverage | Coverage | Coverage |
| North Carolina | None | None | None | None |
| North Dakota | Coverage | Coverage | Coverage | Coverage |
| Ohio | None | Coverage | Coverage | Coverage |

| | | | | |
|-----------------------|----------|----------|----------|----------|
| Oklahoma | None | None | None | Both |
| Oregon | Coverage | Coverage | Coverage | Coverage |
| Pennsylvania | None | None | None | None |
| Rhode Island | Coverage | Coverage | Both | Both |
| South Carolina | None | None | None | None |
| South Dakota | None | Coverage | Coverage | Coverage |
| Tennessee | Coverage | Coverage | Coverage | Coverage |
| Texas | None | None | None | None |
| Utah | None | None | None | Coverage |
| Vermont | Coverage | Coverage | Coverage | Coverage |
| Virginia | Both | Both | Both | Both |
| Washington | None | None | Payment | Payment |
| West Virginia | None | None | Coverage | Coverage |
| Wisconsin | None | None | None | None |
| Wyoming | None | None | None | None |

Note: *None* indicates no relevant telehealth payment or coverage parity laws identified during the respective years. *Both* indicates telehealth payment and coverage parity laws were in effect during the respective years.

Appendix Table 4. Identification of outpatient telehealth encounters

| Description | Value |
|------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| Place of Service | =2 (i.e., telehealth) |
| Procedure Modifier | |
| Synchronous telemedicine service rendered via telephone or other real-time interactive audio-only telecommunications system | =93 |
| Synchronous telemedicine service rendered via real-time interactive audio and visual telecommunication system | =95 |
| Telehealth services for diagnosis, evaluation, or treatment of symptoms of acute stroke | =GO |
| Telehealth service rendered via asynchronous telecommunications system | =GQ |
| Telehealth service rendered via interactive audio and video telecommunication systems | =GT |

Appendix Table 5. Distribution of sample by 50 states and the District of Columbia.

| States | Freq. | Percent % |
|-----------------------|--------------|------------------|
| Alabama | 23,499 | 6.65 |
| Alaska | 169 | 0.05 |
| Arizona | 6,659 | 1.89 |
| Arkansas | 1,663 | 0.47 |
| California | 12,967 | 3.67 |
| Colorado | 2,552 | 0.72 |
| Connecticut | 3,577 | 1.01 |
| Delaware | 1,680 | 0.48 |
| Florida | 22,778 | 6.45 |
| Georgia | 22,904 | 6.48 |
| Hawaii | 38 | 0.01 |
| Idaho | 381 | 0.11 |
| Illinois | 11,347 | 3.21 |
| Indiana | 10,754 | 3.04 |
| Iowa | 1,313 | 0.37 |
| Kansas | 2,449 | 0.69 |
| Kentucky | 22,911 | 6.49 |
| Louisiana | 3,577 | 1.01 |
| Maine | 1,100 | 0.31 |
| Maryland | 6,254 | 1.77 |
| Massachusetts | 7,049 | 2.00 |
| Michigan | 24,050 | 6.81 |
| Minnesota | 1,865 | 0.53 |
| Mississippi | 5,024 | 1.42 |
| Missouri | 6,532 | 1.85 |
| Montana | 296 | 0.08 |
| Nebraska | 709 | 0.20 |
| Nevada | 903 | 0.26 |
| New Hampshire | 740 | 0.21 |
| New Jersey | 9,713 | 2.75 |
| New Mexico | 328 | 0.09 |
| New York | 12,160 | 3.44 |
| North Carolina | 14,250 | 4.03 |
| North Dakota | 174 | 0.05 |
| Ohio | 21,958 | 6.22 |
| Oklahoma | 2,739 | 0.78 |
| Oregon | 5,117 | 1.45 |
| Pennsylvania | 13,663 | 3.87 |
| Rhode Island | 515 | 0.15 |
| South Carolina | 4,741 | 1.34 |
| South Dakota | 572 | 0.16 |
| Tennessee | 9,541 | 2.70 |

| | | |
|-----------------------------|---------|------|
| Texas | 29,030 | 8.22 |
| Utah | 800 | 0.23 |
| Vermont | 478 | 0.14 |
| Virginia | 12,818 | 3.63 |
| Washington | 2,975 | 0.84 |
| District of Columbia | 441 | 0.12 |
| West Virginia | 2,140 | 0.61 |
| Wisconsin | 3,119 | 0.88 |
| Wyoming | 208 | 0.06 |
| Total | 353,220 | 100 |

Appendix Table 6. The association of telehealth payment parity laws with number of hypertension-related telehealth and in-person visits.^a

| | Number of hypertension-related telehealth visits per 1,000 patients | Number of CVD-related telehealth visits per 1,000 patients |
|-------------------------------|----------------------------------------------------------------------------|-------------------------------------------------------------------|
| Payment parity | 2.61** (0.99 - 4.23) | 0.92** (0.23 - 1.61) |
| Covariates | | |
| COVID-19 diagnosis | 111.80*** (107.80 - 115.80) | 21.13*** (19.36 - 22.90) |
| Number of in-person visits | 0.48*** (0.44 - 0.52) | 0.29*** (0.27 - 0.31) |
| Aged 18–34 [reference] | | |
| Aged 35–44 | 5.89** (2.35 - 9.43) | 7.63*** (5.48 - 9.79) |
| Aged 45–54 | -3.90* (-7.25 - -0.55) | 13.32*** (11.14 - 15.50) |
| Aged 55–64 | -8.93*** (-12.38 - -5.48) | 18.62*** (16.26 - 20.97) |
| Male [reference] | | |
| Female | 14.79*** (13.41 - 16.16) | -5.55*** (-6.24 - -4.85) |
| Rural [reference] | | |
| Urban | 31.22*** (29.08 - 33.36) | 6.51*** (5.53 - 7.49) |
| Comorbidities | | |
| Myocardial infarction | -7.53** (-12.72 - -2.34) | 22.05*** (20.10 - 24.00) |
| Congestive heart failure | 2.76 (-1.51 - 7.04) | 26.87*** (24.77 - 28.97) |
| Cerebrovascular | 5.84* (1.17 - 10.51) | 18.36*** (16.60 - 20.13) |
| Peripheral vascular | 6.67 (-0.87 - 14.21) | 16.22*** (13.79 - 18.65) |
| Dementia | -4.72 (-42.64 - 33.20) | 3.72 (-9.24 - 16.68) |
| Chronic pulmonary disease | 12.18*** (9.82 - 14.53) | 5.98*** (4.98 - 6.97) |
| Rheumatic disease | 15.21*** (10.44 - 19.99) | 10.97*** (9.10 - 12.84) |
| Peptic ulcer disease | -3.82 (-14.43 - 6.78) | -2.04 (-5.99 - 1.92) |
| Mild liver disease | 6.08** | 0.13 |

| | | |
|---------------------------------------|-----------------|----------------|
| | (2.21 - 9.94) | (-1.45 - 1.72) |
| Diabetes without chronic complication | 18.25*** | 1.77*** |
| | (16.54 - 19.95) | (1.05 - 2.49) |
| Diabetes with chronic complication | 11.84*** | 3.55*** |
| | (8.72 - 14.95) | (2.33 - 4.78) |
| Hemiplegia or paraplegia | 3.80 | 10.35*** |
| | (-7.92 - 15.51) | (6.94 - 13.76) |
| Renal disease | 57.78*** | 0.30 |
| | (54.15 - 61.40) | (-1.05 - 1.64) |
| Any malignancy | 0.97 | 1.50* |
| | (-2.70 - 4.63) | (0.03 - 2.97) |
| Moderate or severe liver disease | -12.95 | 0.43 |
| | (-30.21 - 4.30) | (-5.34 - 6.19) |
| Metastatic solid tumor | 5.38 | -0.92 |
| | (-6.27 - 17.02) | (-5.44 - 3.61) |
| AIDS/HIV | 64.51*** | 7.53*** |
| | (54.48 - 74.53) | (3.18 - 11.88) |
| State-year level covariates | | |
| Unemployment rates | -0.13 | -0.12 |
| | (-0.94 - 0.67) | (-0.45 - 0.22) |
| GDP per capita | -0.00*** | -0.00 |
| | (-0.00 - -0.00) | (-0.00 - 0.00) |
| Poverty rates | 0.24 | 0.09 |
| | (-0.22 - 0.70) | (-0.11 - 0.29) |
| State fixed effects | Yes | Yes |
| Year fixed effects | Yes | Yes |
| Observations | 353,220 | 353,220 |

Abbreviation: CVD, cardiovascular disease.

^a An exponential hurdle model was used for the number of hypertension- and CVD-related telehealth visits per 1,000 patients. Hypertension- and CVD-related telehealth visits were defined if the visits contained a diagnosis of hypertension (ICD-10-CM=I10-I15) and CVD (ICD-10-CM=I00-I78), respectively. All models were adjusted for state-fixed effects, year-fixed effects, COVID-19 diagnosis, number of in-person visits, patients' age groups, sex, urbanicity of residence, comorbidities, and state-year level time-varying covariates (state-year level unemployment rates, GDP per capita, and poverty rates). Average marginal effects with 95% CI (in parentheses) were reported. All standard errors were clustered by states.

Appendix Table 7. The association of telehealth coverage parity laws with number of hypertension-related telehealth and in-person visits.^a

| | Number of hypertension-related telehealth visits per 1,000 patients | Number of CVD-related telehealth visits per 1,000 patients |
|------------------------------|----------------------------------------------------------------------------|-------------------------------------------------------------------|
| Coverage parity | 1.49 (-0.47 - 3.45) | 0.76 (-0.04 - 1.56) |
| Covariates | | |
| COVID-19 diagnosis | 111.80*** (107.80 - 115.70) | 21.09*** (19.33 - 22.85) |
| Number of in-person visits | 0.48*** (0.44 - 0.52) | 0.29*** (0.27 - 0.31) |
| Aged 18–4 [reference] | | |
| Aged 35–44 | 5.89** (2.35 - 9.43) | 7.62*** (5.47 - 9.77) |
| Aged 45–54 | -3.90* (-7.25 - -0.54) | 13.30*** (11.13 - 15.47) |
| Aged 55–64 | -8.93*** (-12.38 - -5.47) | 18.58*** (16.24 - 20.93) |
| Male [reference] | | |
| Female | 14.79*** (13.41 - 16.16) | -5.54*** (-6.23 - -4.84) |
| Rural [reference] | | |
| Urban | 31.22*** (29.08 - 33.36) | 6.49*** (5.52 - 7.47) |
| Comorbidities | | |
| Myocardial infarction | -7.53** (-12.72 - -2.34) | 22.01*** (20.06 - 23.95) |
| Congestive heart failure | 2.77 (-1.50 - 7.04) | 26.83*** (24.74 - 28.92) |
| Cerebrovascular | 5.83* (1.16 - 10.49) | 18.33*** (16.57 - 20.08) |
| Peripheral vascular | 6.68 (-0.86 - 14.22) | 16.19*** (13.76 - 18.61) |
| Dementia | -4.71 (-42.63 - 33.21) | 3.70 (-9.24 - 16.63) |
| Chronic pulmonary disease | 12.17*** (9.82 - 14.53) | 5.97*** (4.98 - 6.96) |
| Rheumatic disease | 15.22*** (10.44 - 19.99) | 10.95*** (9.08 - 12.82) |
| Peptic ulcer disease | -3.82 (-14.42 - 6.78) | -2.04 (-5.99 - 1.91) |
| Mild liver disease | 6.08** | 0.14 |

| | | |
|---------------------------------------|-----------------|----------------|
| | (2.22 - 9.94) | (-1.45 - 1.72) |
| Diabetes without chronic complication | 18.25*** | 1.77*** |
| | (16.54 - 19.95) | (1.05 - 2.49) |
| Diabetes with chronic complication | 11.83*** | 3.54*** |
| | (8.72 - 14.95) | (2.32 - 4.77) |
| Hemiplegia or paraplegia | 3.78 | 10.33*** |
| | (-7.93 - 15.49) | (6.92 - 13.73) |
| Renal disease | 57.78*** | 0.30 |
| | (54.15 - 61.40) | (-1.05 - 1.64) |
| Any malignancy | 0.97 | 1.50* |
| | (-2.70 - 4.64) | (0.03 - 2.97) |
| Moderate or severe liver disease | -12.97 | 0.43 |
| | (-30.22 - 4.29) | (-5.32 - 6.18) |
| Metastatic solid tumor | 5.38 | -0.92 |
| | (-6.27 - 17.02) | (-5.43 - 3.60) |
| AIDS/HIV | 64.51*** | 7.53*** |
| | (54.49 - 74.54) | (3.19 - 11.86) |
| State-year level covariates | | |
| Unemployment rates | 0.08 | -0.04 |
| | (-0.72 - 0.88) | (-0.37 - 0.29) |
| GDP per capita | -0.00** | -0.00 |
| | (-0.00 - -0.00) | (-0.00 - 0.00) |
| Poverty rates | 0.26 | 0.09 |
| | (-0.21 - 0.74) | (-0.12 - 0.29) |
| State fixed effects | Yes | Yes |
| Year fixed effects | Yes | Yes |
| Observations | 353,220 | 353,220 |

Abbreviation: CVD, cardiovascular disease.

^a An exponential hurdle model was used for the number of hypertension- and CVD-related telehealth visits. Hypertension- and CVD-related telehealth visits were defined if the visits contained a diagnosis of hypertension (ICD-10-CM=I10-I15) and CVD (ICD-10-CM=I00-I78), respectively. All models were adjusted for state-fixed effects, year-fixed effects, COVID-19 diagnosis, number of in-person visits, patients' age groups, sex, urbanicity of residence, comorbidities, and state-year level time-varying covariates (state-year level unemployment rates, GDP per capita, and poverty rates). Average marginal effects with 95% CI (in parentheses) were reported. All standard errors were clustered by states.

Appendix Table 8. Sensitivity analyses of the association of telehealth payment and coverage parity laws with medication adherence, 2018–2021.^a

| Sensitivity analysis | Probit Medication Adherence | OLS Medication Adherence | Probit Medication Adherence | OLS Medication Adherence |
|--------------------------------|-------------------------------------|--------------------------------|-----------------------------------|--------------------------------|
| Payment parity | 0.46* (0.01- 0.92) | 0.46* (0.01 - 0.92) | NA | NA |
| Coverage parity | NA | | 0.10 (-0.37 - 0.57) | 0.10 (-0.37 - 0.57) |
| Covariates | | | | |
| COVID-19 diagnosis | -3.60*** (-4.06 - -3.15) | -3.60*** (-4.06 - -3.15) | -3.61*** (-4.06 - -3.15) | -3.61*** (-4.06 - -3.15) |
| Number of in- person visits | -0.00 (-0.02 - 0.02) | -0.00 (-0.02 - 0.02) | -0.00 (-0.02 - 0.02) | -0.00 (-0.02 - 0.02) |
| Aged 18–34 [reference] | | | | |
| Aged 35–44 | 9.69*** (8.84 – 10.50) | 9.69*** (8.84 - 10.53) | 9.69*** (8.84 – 10.50) | 9.69*** (8.84 - 10.53) |
| Aged 45–54 | 18.50*** (17.70 – 19.30) | 18.53*** (17.74 - 19.33) | 18.50*** (17.70 – 19.30) | 18.53*** (17.74 - 19.33) |
| Aged 55–64 | 24.40*** (23.50 – 25.40) | 24.44*** (23.48 - 25.39) | 24.40*** (23.50 – 25.40) | 24.44*** (23.48 - 25.39) |
| Male [reference] | | | | |
| Female | -3.96*** (-4.41 - -3.51) | -3.96*** (-4.41 - -3.51) | -3.96*** (-4.41 - -3.51) | -3.96*** (-4.41 - -3.51) |
| Rural [reference] | | | | |
| Urban | -0.41 (-1.10 - 0.28) | -0.41 (-1.10 - 0.28) | -0.41 (-1.10 - 0.28) | -0.41 (-1.10 - 0.28) |
| Comorbidities | | | | |
| Myocardial infarction | -0.81 (-1.94 - 0.33) | -0.81 (-1.94 - 0.33) | -0.81 (-1.94 - 0.33) | -0.81 (-1.94 - 0.33) |
| Congestive heart failure | -2.90*** (-3.77 - -2.03) | -2.90*** (-3.77 - -2.03) | -2.90*** (-3.77 - -2.03) | -2.90*** (-3.77 - -2.03) |

| | | | | |
|---------------------------------------|------------------|------------------|------------------|------------------|
| Cerebrovascular | -0.85 | -0.85 | -0.85 | -0.85 |
| | (-1.75 - 0.04) | (-1.75 - 0.04) | (-1.75 - 0.04) | (-1.75 - 0.04) |
| Peripheral vascular | -3.01*** | -3.01*** | -3.01*** | -3.01*** |
| | (-4.56 - -1.46) | (-4.56 - -1.46) | (-4.56 - -1.46) | (-4.56 - -1.46) |
| Dementia | -10.20** | -10.22** | -10.2** | -10.22** |
| | (-17.30 - -3.15) | (-17.29 - -3.15) | (-17.30 - -3.15) | (-17.29 - -3.15) |
| Chronic pulmonary disease | -3.50*** | -3.50*** | -3.50*** | -3.50*** |
| | (-4.05 - -2.95) | (-4.05 - -2.95) | (-4.05 - -2.95) | (-4.05 - -2.95) |
| Rheumatic disease | -2.30*** | -2.30*** | -2.30*** | -2.30*** |
| | (-3.39 - -1.22) | (-3.39 - -1.22) | (-3.39 - -1.22) | (-3.39 - -1.22) |
| Peptic ulcer disease | -9.59*** | -9.59*** | -9.59*** | -9.59*** |
| | (-11.0 - -7.84) | (-11.34 - -7.84) | (-11.3 - -7.84) | (-11.34 - -7.84) |
| Mild liver disease | -2.44*** | -2.44*** | -0.0244*** | -2.44*** |
| | (-3.41 - -1.47) | (-3.41 - -1.47) | (-3.41 - -1.47) | (-3.41 - -1.47) |
| Diabetes without chronic complication | 1.45*** | 1.45*** | 1.45*** | 1.45*** |
| | (1.05 - 1.84) | (1.05 - 1.84) | (1.05 - 1.84) | (1.05 - 1.84) |
| Diabetes with chronic complication | -2.04*** | -2.04*** | -2.03*** | -2.03*** |
| | (-2.68 - -1.39) | (-2.68 - -1.39) | (-2.68 - -1.39) | (-2.68 - -1.39) |
| Hemiplegia or paraplegia | -2.78* | -2.78* | -2.78* | -2.78* |
| | (-5.35 - -2.21) | (-5.35 - -0.22) | (-5.35 - -0.22) | (-5.35 - -0.22) |
| Renal disease | -2.02*** | -2.02*** | -2.02*** | -2.02*** |
| | (-2.75 - -1.29) | (-2.75 - -1.29) | (-2.75 - -1.29) | (-2.75 - -1.29) |
| Any malignancy | 1.63*** | 1.63*** | 1.63*** | 1.63*** |
| | (0.82 - 2.45) | (0.82 - 2.45) | (0.82 - 2.45) | (0.82 - 2.45) |
| Moderate or severe liver disease | -10.2*** | -10.21*** | -10.2*** | -10.21*** |
| | (-14.40 - -6.04) | (-14.37 - -6.04) | (-14.40 - -6.04) | (-14.37 - -6.04) |
| Metastatic solid tumor | -7.18*** | -7.18*** | -7.18*** | -7.18*** |
| | (-9.14 - -5.22) | (-9.14 - -5.22) | (-9.14 - -5.22) | (-9.14 - -5.22) |

| | | | | |
|-----------------------------|----------------|----------------|----------------|----------------|
| AIDS/HIV | 2.94** | 2.94** | 2.94** | 2.94** |
| | (1.16 - 4.72) | (1.16 - 4.72) | (1.16 - 4.72) | (1.16 - 4.72) |
| State-year level covariates | | | | |
| Unemployment rates | 0.31* | 0.31* | 0.30* | 0.29* |
| | (0.06 - 0.56) | (0.06 - 0.56) | (0.04 - 0.55) | (0.04 - 0.55) |
| GDP per capita | -0.00 | -0.00 | -0.00 | -0.00 |
| | (-0.00 - 0.00) | (-0.00 - 0.00) | (-0.00 - 0.00) | (-0.00 - 0.00) |
| Poverty rates | 0.04 | 0.04 | 0.03 | 0.03 |
| | (-0.11 - 0.19) | (-0.11 - 0.19) | (-0.12 - 0.18) | (-0.12 - 0.18) |
| State fixed effects | Yes | Yes | Yes | Yes |
| Year fixed effects | Yes | Yes | Yes | Yes |
| Observations | 353,220 | 353,220 | 353,220 | 353,220 |

Abbreviation: NA, not available.

^a A probit and OLS were used as sensitivity analyses for the medication adherence dependent variable. All models were adjusted for state-fixed effects, year-fixed effects, COVID-19 diagnosis, number of in-person visits, patients' age groups, sex, urbanicity of residence, comorbidities, and state-year level time-varying covariates (state-year level unemployment rates, GDP per capita, and poverty rates). Average marginal effects with 95% CI (in parentheses) were reported. All standard errors were clustered by states.

Appendix Table 9. Sensitivity analyses of the association of telehealth payment and coverage parity laws with average number of drug supply per antihypertensive drug, 2018–2021.^a

| | ZINB | ZINB |
|-----------------------------------|--------------------------------|--------------------------------|
| | Average days of drug supply | Average days of drug supply |
| Payment parity | 1.88 (-0.11 - 3.86) | NA |
| Coverage parity | NA | 1.92 (-0.01 - 3.86) |
| Covariates | | |
| COVID-19 diagnosis | -3.49*** (-4.47 - -2.51) | -3.49*** (-4.48 - -2.51) |
| Number of in-person visits | -0.10*** (-0.13 - -0.07) | -0.10*** (-0.13 - -0.07) |
| Aged 18–34 [reference] | | |
| Aged 35–44 | 12.47*** (11.38 - 13.56) | 12.47*** (11.38 - 13.56) |
| Aged 45–54 | 21.95*** (20.51 - 23.39) | 21.95*** (20.51 - 23.39) |
| Aged 55–64 | 26.74*** (24.68 - 28.79) | 26.74*** (24.68 - 28.80) |
| Male [reference] | | |
| Female | -9.14*** (-10.10 - -8.19) | -9.14*** (-10.10 - -8.19) |
| Rural [reference] | | |
| Urban | 6.23*** (3.01 - 9.45) | 6.23*** (3.01 - 9.45) |
| Comorbidities | | |
| Myocardial infarction | -18.62*** (-20.16 - -17.08) | -18.62*** (-20.16 - -17.08) |
| Congestive heart failure | -23.53*** (-25.22 - -21.84) | -23.53*** (-25.22 - -21.84) |
| Cerebrovascular | -10.40*** (-11.56 - -9.231) | -10.39*** (-11.56 - -9.23) |
| Peripheral vascular | -12.99*** (-15.30 - -10.67) | -12.99*** (-15.30 - -10.67) |
| Dementia | -29.33*** (-39.33 - -19.33) | -29.33*** (-39.33 - -19.34) |
| Chronic pulmonary disease | -6.49*** (-7.39 - -5.58) | -6.49*** (-7.39 - -5.58) |
| Rheumatic disease | -4.91*** (-6.74 - -3.09) | -4.91*** (-6.74 - -3.09) |
| Peptic ulcer disease | -15.25*** | -15.24*** |

| | | |
|----------------------------------------------|-------------------|-------------------|
| | (-18.37 - -12.12) | (-18.37 - -12.11) |
| Mild liver disease | -5.91*** | -5.91*** |
| | (-7.60 - -4.23) | (-7.60 - -4.23) |
| Diabetes without chronic complication | 8.54*** | 8.54*** |
| | (7.76 - 9.33) | (7.76 - 9.33) |
| Diabetes with chronic complication | -1.71*** | -1.71*** |
| | (-2.46 - -0.96) | (-2.46 - -0.96) |
| Hemiplegia or paraplegia | -12.89*** | -12.88*** |
| | (-18.18 - -7.60) | (-18.18 - -7.59) |
| Renal disease | -13.87*** | -13.86*** |
| | (-15.77 - -11.96) | (-15.77 - -11.96) |
| Any malignancy | -0.28 | -0.28 |
| | (-1.65 - 1.10) | (-1.65 - 1.10) |
| Moderate or severe liver disease | -35.11*** | -35.11*** |
| | (-40.82 - -29.41) | (-40.82 - -29.41) |
| Metastatic solid tumor | -12.35*** | -12.35*** |
| | (-16.96 - -7.74) | (-16.96 - -7.74) |
| AIDS/HIV | -8.00*** | -8.00*** |
| | (-11.93 - -4.07) | (-11.93 - -4.07) |
| State-year level covariates | | |
| Unemployment rates | -0.28 | -0.22 |
| | (-1.00 - 0.43) | (-0.92 - 0.49) |
| GDP per capita | -0.00 | -0.00 |
| | (-0.00 - 0.00) | (-0.00 - 0.00) |
| Poverty rates | -0.21 | -0.29* |
| | (-0.44 - 0.02) | (-0.51 - -0.06) |
| | | |
| State fixed effects | Yes | Yes |
| Year fixed effects | Yes | Yes |
| Observations | 353,220 | 353,220 |

Abbreviations: ZINB, zero-inflated negative binomial; NA, not available.

^a A zero-inflated negative binomial model was used for sensitivity analysis. The logit model was used to model zero outcomes (first part). A negative binomial model was used to model the number of average days of drug supply (second part). The first part was adjusted for COVID-19 diagnosis, number of in-person visits, patients' age groups, sex, urbanicity of residence, and comorbidities. The second part was adjusted for state-fixed effects, year-fixed effects, COVID-19 diagnosis, number of in-person visits, patients' age groups, sex, urbanicity of residence, comorbidities, and state-year level time-varying covariates (state-year level unemployment rates, GDP per capita, and poverty rates). Average marginal effects with 95% CI were reported. All standard errors were clustered by states.